Who makes Dexmetomidine intrathecally?

Dexmetomidine intrathecally is developed by KAT General Hospital.

What development phase is Dexmetomidine intrathecally in?

Dexmetomidine intrathecally is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Dexmetomidine intrathecally

KAT General Hospital · FDA-approved active Small molecule Quality 2/100

Dexmetomidine intrathecally, marketed by KAT General Hospital, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique mechanism of action that may offer a competitive edge. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Dexmetomidine intrathecally
Also known as	DEX
Sponsor	KAT General Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dexmetomidine intrathecally CI brief — competitive landscape report
Dexmetomidine intrathecally updates RSS · CI watch RSS
KAT General Hospital portfolio CI